Cargando…

(18)F-MK-6240 tau-PET in genetic frontotemporal dementia

Tau is one of several proteins associated with frontotemporal dementia. While knowing which protein is causing a patient’s disease is crucial, no biomarker currently exists for identifying tau in vivo in frontotemporal dementia. The objective of this study was to investigate the potential for the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levy, Jake P, Bezgin, Gleb, Savard, Melissa, Pascoal, Tharick A, Finger, Elizabeth, Laforce, Robert, Sonnen, Joshua A, Soucy, Jean-Paul, Gauthier, Serge, Rosa-Neto, Pedro, Ducharme, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166561/ https://www.ncbi.nlm.nih.gov/pubmed/34664612 http://dx.doi.org/10.1093/brain/awab392

Ejemplares similares

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [(18)F]MK6240 Tau PET in Target Regions
por: Tissot, Cécile, et al.
Publicado: (2023)

Cryo-EM structure of Alzheimer’s disease tau filaments with PET ligand MK-6240
por: Kunach, Peter, et al.
Publicado: (2023)

Optimizing quantification of MK6240 tau PET in unimpaired older adults
por: Harrison, Theresa M., et al.
Publicado: (2023)

Visually Identified Tau (18)F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease
por: Krishnadas, Natasha, et al.
Publicado: (2022)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Development, initial validation, and application of a visual read method for [(18)F]MK‐6240 tau PET
por: Shuping, Joanna L., et al.
Publicado: (2023)

A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2021)

Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue
por: Aguero, Cinthya, et al.
Publicado: (2019)

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL (18)F-MK6240 PET study
por: Krishnadas, Natasha, et al.
Publicado: (2023)

Dosimetry and efficacy of a tau PET tracer [(18)F]MK-6240 in Japanese healthy elderly and patients with Alzheimer’s disease
por: Ohnishi, Akihito, et al.
Publicado: (2022)

Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer’s disease spectrum
por: Belasso, Clyde J., et al.
Publicado: (2023)

A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [(18)F]MK-6240
por: Kolinger, Guilherme D., et al.
Publicado: (2021)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
por: Macedo, Arthur C., et al.
Publicado: (2023)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
por: Fernández Arias, Jaime, et al.
Publicado: (2023)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Case Report: (18)F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player
por: Krishnadas, Natasha, et al.
Publicado: (2020)

Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
por: Therriault, Joseph, et al.
Publicado: (2023)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
por: Therriault, Joseph, et al.
Publicado: (2021)

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Imaging Alzheimer's disease pathophysiology with PET
por: Schilling, Lucas Porcello, et al.
Publicado: (2016)

Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
por: Wang, Yi-Ting T, et al.
Publicado: (2021)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment
por: Gauthier, Serge, et al.
Publicado: (2018)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment
por: Therriault, Joseph, et al.
Publicado: (2021)

Medial temporal tau predicts memory decline in cognitively unimpaired elderly
por: Kwan, Angela T H, et al.
Publicado: (2022)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
por: Li, Xiaofeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2aj5b749g2pof70ldho3vmkpo0